PubRank

R A McClelland

Author PubWeight™ 68.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998 6.86
2 Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995 3.88
3 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995 1.91
4 Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet 1987 1.46
5 Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2005 1.41
6 Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol 1986 1.39
7 The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003 1.29
8 Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994 1.27
9 Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994 1.25
10 Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988 1.22
11 Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993 1.22
12 Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999 1.20
13 Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001 1.08
14 Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 1987 1.06
15 Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur J Cancer 1994 1.06
16 Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991 1.06
17 EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998 1.05
18 Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 1996 1.04
19 Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990 1.03
20 Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 1989 1.02
21 Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 2002 1.01
22 Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol 1987 0.95
23 Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clin Cancer Res 1997 0.95
24 Differential expression of oestrogen regulated genes in breast cancer. Acta Oncol 1995 0.95
25 Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res 1987 0.94
26 Targeting radiosensitizers to DNA by attachment of an intercalating group: nitroimidazole-linked phenanthridines. Radiat Res 1991 0.93
27 Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 2006 0.89
28 The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. Eur J Cancer 1993 0.89
29 Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 1986 0.89
30 DNA-targeted 2-nitroimidazoles: in vitro and in vivo studies. Br J Cancer 1994 0.88
31 Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992 0.88
32 Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res 1984 0.88
33 Ovulation induction and endometrial steroid receptors. Hum Reprod 1994 0.88
34 Mechanistic studies of enhanced in vitro radiosensitization and hypoxic cell cytotoxicity by targeting radiosensitizers to DNA via intercalation. Int J Radiat Oncol Biol Phys 1992 0.86
35 Effect of 1-methyl-2-nitrosoimidazole on intracellular thiols and calcium levels in Chinese hamster ovary cells. Biochem Pharmacol 1991 0.84
36 Preparation, toxicity and mutagenicity of 1-methyl-2-nitrosoimidazole. A toxic 2-nitroimidazole reduction product. Biochem Pharmacol 1988 0.84
37 Mechanism of the selective hypoxic cytotoxicity of 1-methyl-2-nitroimidazole. Biochem Pharmacol 1994 0.84
38 Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg 1998 0.83
39 Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors. Cancer Res 1989 0.83
40 Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994 0.82
41 The oxygen dependence of the reduction of nitroimidazoles in a radiolytic model system. Int J Radiat Oncol Biol Phys 1984 0.82
42 NLP-1: a DNA intercalating hypoxic cell radiosensitizer and cytotoxin. Int J Radiat Oncol Biol Phys 1989 0.81
43 Intramolecular hemiacetals. The acid-base-catalyzed ring-chain interconversion of 2-substituted 2-hydroxy-4,4-dimethylmorpholinium cations in aqueous solution. Acta Chem Scand 1991 0.81
44 Growth factor stimulation of proliferating cell nuclear antigen (PCNA) in human breast epithelium in organ culture. Cell Biol Int Rep 1991 0.80
45 Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 1994 0.80
46 Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin Hematol 1990 0.80
47 2-Hydroxylaminoimidazoles--unstable intermediates in the reduction of 2-nitroimidazoles. Biochem Pharmacol 1984 0.79
48 Cytotoxicity and glutathione depletion by 1-methyl-2-nitrosoimidazole in human colon cancer cells. Biochem Pharmacol 1989 0.79
49 Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer 1992 0.78
50 Isolation and characterization of a cell line resistant to 5-[3-(2-nitro-1-imidazoyl)-propyl]-phenanthridinium bromide (2-NLP-3), a DNA-intercalating hypoxic cell radiosensitizer and cytotoxin. Biochem Pharmacol 1995 0.78
51 1-Methyl-2-nitrosoimidazole: cytotoxic and glutathione depleting capabilities. Int J Radiat Oncol Biol Phys 1989 0.78
52 Depletion of intracellular glutathione by 1-methyl-2-nitrosoimidazole. Int J Radiat Oncol Biol Phys 1992 0.78
53 A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J Pathol 1995 0.78
54 Oxidative stress and 1-methyl-2-nitroimidazole cytotoxicity. Biochem Pharmacol 1998 0.77
55 Covalent binding of carbamazepine oxidative metabolites to neutrophils. Drug Metab Dispos 1995 0.77
56 Radiosensitizing and cytotoxic properties of DNA targeted phenanthridine-linked nitroheterocycles of varying electron affinities. Int J Radiat Biol 1994 0.77
57 Modulation of oestrogen action by receptor gene inhibition. Eur J Cancer 2000 0.77
58 Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases. Drug Metab Dispos 1995 0.77
59 Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci 1996 0.76
60 Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Ann N Y Acad Sci 1990 0.76
61 Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer. J Steroid Biochem Mol Biol 1990 0.76
62 A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines. Histochem J 1994 0.75
63 Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol 1995 0.75
64 Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1995 0.75
65 Apoptosis and 1-methyl-2-nitroimidazole toxicity in CHO cells. Br J Cancer 1997 0.75
66 The production of strand breaks in DNA in the presence of the hydroxylamine of SR-2508 (1-[N-(2-hydroxyethyl)acetamido]-2-nitroimidazole) at neutral pH. Int J Radiat Oncol Biol Phys 1986 0.75
67 Equilibrium constants and rate constants for the transformations in aqueous solution of a spirocyclic hydroxyphosphorane. J Am Chem Soc 1986 0.75
68 Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. Bone Marrow Transplant 1993 0.75
69 Risk factors and clinical data related to oestrogen receptor status in women presenting with breast cancer. Br J Surg 1985 0.75
70 Stable reduction product of misonidazole. Int J Radiat Oncol Biol Phys 1986 0.75
71 DNA damage induced in HT-29 colon cancer cells by exposure to 1-methyl-2-nitrosoimidazole, a reductive metabolite of 1-methyl-2-nitroimidazole. Biochem Pharmacol 1991 0.75
72 Enhancement of melphalan (L-PAM) toxicity by reductive metabolites of 1-methyl-2-nitroimidazole, a model nitroimidazole chemosensitizing agent. Biochem Pharmacol 1990 0.75
73 [Sensory defects, physical deformity and somatic diseases in schizophrenia]. Vestn Akad Med Nauk SSSR 1971 0.75